Amneal Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.0 | $2.8 | $2.4 | $2.2 | $2.1 |
| Operating income | $0.4 | $0.2 | $0.2 | -$0.1 | $0.2 |
| Net income | $0.1 | -$0.1 | -$0.1 | -$0.3 | $<0.1 |
| Balance Sheet | |||||
| Total debt | $2.7 | $2.5 | $2.5 | $2.6 | $2.7 |
| Cash Flow Statement | |||||
| Free cash flow | $0.3 | $0.2 | $0.3 | $<0.1 | $0.2 |
Shares outstanding 319.4M · Free float 22.9%
Annual filing data through FY ended December 31, 2025; float as of September 12, 2026.
Earnings
Other Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 10, 2026
Deals
Amneal Completes Acquisition of Kashiv BioSciences
July 4, 2026
Guidance Season
Chipmakers Lead a Guidance Season Almost Free of Cuts